Denali Therapeutics Inc.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $74.5M | $75.7M |
| SG&A Expense | $15.7M | $11.7M |
| Operating Income | $-90.1M | $-87.4M |
| Operating Margin | — | — |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | $0 | — |
| Net Income | $-88.2M | $-86.7M |
| Net Margin | — | — |
| EPS (Basic) | $-5.89 | $-13.49 |
| EPS (Diluted) | $-5.89 | $-13.49 |
| Shares Outstanding (Basic) | 87.5M | — |
| Shares Outstanding (Diluted) | 87.5M | — |
| Dividends Per Share | — | — |